Yung Zip Chemical Ind. Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 09, 2023
Share
Yung Zip Chemical Ind. Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 136.84 million compared to TWD 154.65 million a year ago. Net income was TWD 9.18 million compared to TWD 33.32 million a year ago. Basic earnings per share from continuing operations was TWD 0.22 compared to TWD 0.79 a year ago. Diluted earnings per share from continuing operations was TWD 0.22 compared to TWD 0.79 a year ago.
For the six months, sales was TWD 272.6 million compared to TWD 262.79 million a year ago. Net income was TWD 27.21 million compared to TWD 38.61 million a year ago. Basic earnings per share from continuing operations was TWD 0.64 compared to TWD 0.91 a year ago. Diluted earnings per share from continuing operations was TWD 0.64 compared to TWD 0.91 a year ago.
YUNG ZIP CHEMICAL IND. CO., LTD. is a Taiwan-based company principally engaged in the manufacturing and trading of pharmaceutical ingredient products. Its diclofenac sodium (DCS) is used for the treatment of rheumatoid arthritis, bursitis and inflammation. The acyclovir (ACV) is used for the treatment of herpes virus infections. The miconazole nitrate (MCN) is used for the treatment of yeast infection. The sodium starch glycolate (SSG) is used as disintegrant in pharmaceutical preparation. The Clonidine hydrochloride (CLD) is used for the treatment of hypertension. The Company mainly distributes its products in domestic market and overseas markets, including the United States of America (the USA), Thailand, Indonesia and the Philippines.
YUNG ZIP CHEMICAL IND. CO., LTD. 
